Cannabidiol as a Treatment for Mood Disorders : A Systematic Review Le cannabidiol comme traitement des troubles de l’humeur : une revue systématique Jairo Vinicius Pinto, MD, Gayatri Saraf, MD, Christian Frysch, MD, Daniel Vigo, MD, DrPH, Kamyar Keramatian, MD, MSc, FRCPC, Trisha Chakrabarty, MD, Raymond W. Lam, MD, Marcia Kauer-Sant’Anna, MD, PhD, and Lakshmi N. Yatham, MBBS, FRCPC The Canadian Journal of Psychiatry /La Revue Canadienne de Psychiatrie, 2020, Vol. 65, (4), 213-227. Doi : 10.1177/0706743719895195 Abstract Objective : To review the current evidence for efficacy of cannabidiol in the treatment of mood disorders. Methods : We systematically searched PubMed, Embase, Web of Science, PsychInfo, Scielo, [...]
Lire la suiteRole of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders Francisco Navarrete, María Salud García-Gutiérrez, Ani Gasparyan, Amaya Austrich-Olivares and Jorge Manzanares Frontiers in Pharmacology, 2021, 12, Article 696010, 1-24. Doi : 10.3389/fphar.2021.626010 Drug treatments available for the management of substance use disorders (SUD) present multiple limitations in efficacy, lack of approved treatments or alarming relapse rates. These facts hamper the clinical outcome and the quality of life of the patients supporting the importance to develop new pharmacological agents. Lately, several reports suggest that cannabidiol (CBD) presents beneficial effects relevant for the management of neurological disorders such as epilepsy, multiple sclerosis, Parkinson’s, or [...]
Lire la suiteCB2 Receptor Involvement in the Treatment of Substance Use Disorders Francisco Navarrete, María S. García-Gutiérrez, Ani Gasparyan, Daniela Navarro and Jorge Manzanares Biomolecules, 2021, 11, 1556, 1-18. Doi : 10.3390/biom11111556 Abstract The pharmacological modulation of the cannabinoid receptor 2 (CB2r) has emerged as a promising potential therapeutic option in addiction. The purpose of this review was to determine the functional involvement of CB2r in the effects produced by drugs of abuse at the central nervous system (CNS) level by assessing evidence from preclinical and clinical studies. In rodents, several reports suggest the functional involvement of CB2r in the effects produced by drugs of abuse such [...]
Lire la suiteInvolvement of the endocannabinoid system in drug addiction, Rafael Maldonado, Olga Valverde and Fernando Berrendero Trends in Neurosciences, 2006, 29, (4), 225-232. Doi : 10.1016/j.tins.2006.01.008 Recent studies have shown that the endocannabinoid system is involved in the common neurobiological mechanism underlying drug addiction. This system participates in the primary rewarding effects of cannabinoids, nicotine, alcohol and opioids, through the release of endocannabinoids in the ventral tegmental area. Endocannabinoids are also involved in the motivation to seek drugs by a dopamine-independent mechanism, demonstrated for psychostimulants and opioids. The endocannabinoid system also participates in the common mechanisms underlying relapse to drugseeking behaviour by mediating the motivational effects [...]
Lire la suiteCannabinoids, Pain, and Opioid Use Reduction : The Importance of Distilling and Disseminating Existing Data Kent E. HUTCHISON, Sarah L. HAGERTY, Jeffrey GALINKIN, Angela D. BRYAN, L. Cinnamon BIDWELL Cannabis and Cannabinoid Research, 2019, 4, (3), 158-164. Doi : 10.1089/can.2018.0052 Abstract The high prevalence of chronic pain conditions combined with an over-reliance on opioid prescriptions has resulted in an opioid epidemic and a desperate need for solutions. There is some debate about whether cannabis might play a role in addressing chronic pain conditions as well as the opioid epidemic. Recent surveys suggest that a large number of people are using cannabis as a treatment for [...]
Lire la suiteMedical cannabis authorization and the risk of cardiovascular events : a longitudinal cohort study Arsene Zongo, Cerina Lee, Jason R. B. Dyck, Jihane El‑Mourad, Elaine Hyshka, John G. Hanlon and Dean T. Eurich BMC Cardiovascular Disorders, 2021, 21, 426 doi : 10.1186/s12872-021-02229-6 Abstract Background : Cannabis is increasingly used for therapeutic purpose. However, its safety profile is not well known. This study assessed the risk of cardiovascular-related emergency department (ED) visit and hospitalization in adult patients authorized to use medical cannabis in Ontario, Canada from 2014 to 2017. Methods : This is a longitudinal cohort study of patients who received medical cannabis authorization and followedup in [...]
Lire la suiteReal life Experience of Medical Cannabis Treatment in Autism : Analysis of Safety and Efficacy Lihi Bar-Lev Schleider, Raphael Mechoulam, Naama Saban, Gal Meiri & Victor Novack Scientific Reports, Nature.com, 2019, 9, 200, 1-7 Doi : 10.1038/s41598-018-37570-y There has been a dramatic increase in the number of children diagnosed with autism spectrum disorders (ASD) worldwide. Recently anecdotal evidence of possible therapeutic effects of cannabis products has emerged. The aim of this study is to characterize the epidemiology of ASD patients receiving medical cannabis treatment and to describe its safety and efficacy. We analysed the data prospectively collected as part of the treatment program of [...]
Lire la suiteCurrent state of evidence of cannabis utilization for treatment of autism spectrum disorders Rumi Agarwal, Shanna L. Burke and Marlaina Maddux BMC Psychiatry, 2019, 19, 328 Doi : 10.1186/s12888-019-2259-4 Abstract The core symptoms and co-morbidities associated with autism spectrum disorders (ASD) affect daily living and quality of life. Existing pharmacological interventions are only able to attenuate some related symptoms but are unable to address the underlying etiologies associated with ASD. Anecdotal evidence, which claims benefit from the use of cannabis to treat symptoms among this population, has been gaining popularity as families seek solutions. This paper analyzed recent peer-reviewed literature to identify the current state of [...]
Lire la suiteThe effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD) Charlotte M. Pretzsch, Bogdan Voinescu, Maria A. Mendez, Robert Wichers, Laura Ajram, Glynis Ivin, Martin Heasman, Steven Williams, Declan GM Murphy, Eileen Daly and Gráinne M. McAlonan Journal of Psychopharmacology, 2019, Vol. 33, (9), 1141–1148 Doi : 10.1177/0269881119858306 Abstract Background : The potential benefits of cannabis and its major non-intoxicating component cannabidiol (CBD) are attracting attention, including as a potential treatment in neurodevelopmental disorders such as autism spectrum disorder (ASD). However, the neural action of CBD, and its relevance to ASD, remains [...]
Lire la suiteEffects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, 2019, volume 10, Article 1146, 1-9. doi : 10.3389/fneur.2019.01145 Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]
Lire la suite